Parkinson disease (PD) is the most common neurodegenerative movement disorder. In
Europe, prevalence and incidence rates for PD are estimated at approximately 108–257/100 …

Neurodegenerative diseases are progressive degenerative conditions characterized by the
functional deterioration and ultimate loss of neurons. These incurable and debilitating …

Nanomedicine-based anti-neuroinflammation strategy has become a promising dawn of
Parkinson's disease (PD) treatment. However, there are significant gaps in our …

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the gradual loss
of midbrain dopaminergic neurons in association with aggregation of α-synuclein. Oxidative …

After more than two decades of preclinical and clinical studies, on August 27, 2019, the US
Food and Drug Administration (FDA) approved the adenosine A 2A receptor antagonist …

This study aimed to determine the mutational spectrum of familial Parkinson's disease and
sporadic early-onset Parkinson's disease (sEOPD) in a mainland Chinese population and …

Abstract Parkinson's disease (PD), a neurodegenerative disease that shows a high
incidence in older individuals, is becoming increasingly prevalent. Unfortunately, there is no …

Oxindole derivatives are known for their great interest in the field of Medicinal Chemistry, as
they display vast biological activities. Recent efforts concerning the preparation of oxindole …

Parkinson's disease (PD) is one of the most debilitating brain diseases. Despite the
availability of symptomatic treatments, response towards the health of PD patients remains …

Glial cell‐dominated inflammatory microenvironment and neuronal damage due to oxidative
stress are major impediments to the treatment of central nervous degenerative diseases …